Egr-1: A Target for Scleroderma Therapy PDF Print E-mail
Monday, 26 April 2010 15:10
Two separate research groups funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue becomes thick, hard, and rigid, hindering normal tissue and organ function. Controlling EGR-1, say the scientists, could be a potential therapy for such disorders as Scleroderma and pulmonary fibrosis. Their findings have been reported in the American Journal of Pathology.

Fibrosis is a disorder of the extracellular matrix, the mesh of proteins like collagen that makes up the body’s connective tissue. It is a factor in scleroderma, among other diseases, and can affect many of the body’s organs, including the lungs, liver, and skin. Its consequences can be devastating, even leading to death. Recent research has shown that cells in fibrotic tissue receive the wrong molecular signals, causing too many extracellular proteins to be made. One possible way to approach the fibrosis problem, scientists say, might be to try to interrupt such signals at critical points in the cellular pathways that they travel.

The two research groups, headed by Carol Feghali-Bostwick, Ph.D., at the University of Pittsburgh School of Medicine and John Varga, M.D ., at Northwestern University’s Feinberg School of Medicine, took separate approaches in discovering the importance of EGR-1. The University of Pittsburgh group induced fibrosis in mouse and human fibroblasts (cells that make up the extracellular matrix) by utilizing a signaling protein called IGFBP-5 (insulin-like growth factor binding protein 5). The Northwestern team administered the antibiotic bleomycin to induce scleroderma in mice. Both research teams found that the experimentally produced fibrosis was associated with abnormally elevated EGR-1 activity.

Furthermore, when they produced fibrosis in cells or in mice lacking EGR-1, the amounts of fibrosis were dramatically reduced. In further support of the findings, the Pittsburgh group found that EGR-1 levels were higher in lung tissues and fibroblasts of people with pulmonary fibrosis compared to controls. EGR-1, concluded the scientists, appears to be essential for the development of fibrosis, making it a potential target for therapy. The two studies also showed that independent signaling pathways, such as those for IGFBP-5 and bleomycin, both converge on EGR-1 to create fibrosis.

Fibrosis is a common disorder and a serious complication of many diseases. It is still considered hard to treat, with no currently approved therapies. Because the understanding of fibrosis is a major unmet medical need, any fresh insights into the disease process might open the door for novel therapies.

Source: 7th Space
 
More articles :

» Study Suggests Link Between Scleroderma, Cancer in Certain Patients

Patients with a certain type of may get cancer and scleroderma simultaneously, Johns Hopkins researchers have found, suggesting that in some diseases, autoimmunity and cancer may be linked.These findings could lead researchers closer to discovering...

» Rituximab for Scleroderma: Does Something Finally Work?

Kevin Deane, MDPosted: 03/10/2010Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle StudyDaoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280BackgroundMultiple drugs have been tried in...

» UT Researchers At Forefront Of Efforts To Stem The Tide Of Autoimmune Diseases

Autoimmune and autoinflammatory diseases are on the rise and researchers and physicians at are at the forefront of efforts to stem the tide. These diseases are often hard to diagnose and often affect individuals differently.Autoimmune and...

» The Scleroderma Foundation Teams Up with Traitwise

The has teamed up with Austin, TX company, Incorporated, to launch a unique survey to poll thousands of patients and their caregivers. Data from the survey will be shared with researchers nationally and internationally in an effort to improve...

» New Classification Criteria Developed For Scleroderma

The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the and and should allow patients to be identified and treated earlier, according to the professional bodies.Published in Arthritis and Rheumatism, the...

» Preliminary Results Show Beneficial Effects of Imatinib in Scleroderma

Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing beneficial effects on skin and lung manifestations in patients with diffuse cutaneous scleroderma....

Comments  

 
+1 #2 Nia 2012-09-16 23:51
i hve sd, very grateful for this research. wouldnt be suprised if there's a vaccine for autoimmune doseases in the not too distant future.
Report to administrator
 
 
+1 #1 Nia 2012-09-16 23:50
Quote:
exciting!
didnt know SD could be induced with an antibiotic...
Report to administrator